Acumapimod - Mereo BioPharma

Drug Profile

Acumapimod - Mereo BioPharma

Alternative Names: Acumapimod; BCT-197; BCT197A2201

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Mereo BioPharma; Novartis
  • Class Anti-inflammatories; Antibronchitics; Benzamides; Cyclopropanes; Pyrazoles; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Discontinued Acute kidney injury

Most Recent Events

  • 19 Mar 2018 Mereo BioPharma initiates enrolment in a phase I trial for Healthy volunteers in USA (NCT03498170)
  • 13 Dec 2017 Acumapimod - Mereo BioPharma is available for licensing as of 13 Dec 2017. http://www.mereobiopharma.com/
  • 11 Dec 2017 Positive top-line efficacy and adverse events data from the phase II trial in Chronic obstructive pulmonary disease released by Mereo BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top